While North America remains the most mature Leuprolide Acetate market region, the Asia-Pacific region is currently the fastest-growing in 2026. Countries like China and India have significantly expanded their public health insurance schemes to cover advanced cancer treatments, making Leuprolide injections accessible to hundreds of millions for the first time. In Japan and South Korea, the...